Viridian net loss widens to $127.12 million in Q2 FY26; SG&A expenses climb to $54.98 million

Reuters2026/08/06 11:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Viridian Therapeutics posted a GAAP net loss of $127.12 million, widening from $100.74 million a year earlier.
GAAP revenue rose to $284,000 from $75,000, driven by $233,000 of license revenue.
R&D expense fell to $71.58 million from $86.63 million, while SG&A jumped to $54.98 million from $20.22 million on commercial build-out.
Cash, cash equivalents, and marketable securities climbed to $981.53 million at June 30 from $762.2 million at March 31.
Lumvoa won FDA approval for thyroid eye disease on June 26 and launched in the U.S.; elegrobart remains on track for BLA submission in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viridian Therapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Viridian net loss widens to $127.12 million in Q2 FY26; SG&A expenses climb to $54.98 million

You may also like

Crypto prices